Norinchukin Bank The boosted its holdings in Mylan (NASDAQ:MYL) by 7.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 42,877 shares of the company’s stock after buying an additional 2,961 shares during the quarter. Norinchukin Bank The’s holdings in Mylan were worth $1,814,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of MYL. Meeder Asset Management Inc. increased its position in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after purchasing an additional 1,475 shares during the last quarter. Rational Advisors LLC purchased a new stake in shares of Mylan during the 4th quarter valued at about $190,000. BT Investment Management Ltd purchased a new stake in shares of Mylan during the 3rd quarter valued at about $142,000. Advisor Partners LLC purchased a new stake in Mylan in the 4th quarter worth approximately $214,000. Finally, First Personal Financial Services increased its holdings in Mylan by 77.1% in the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock worth $205,000 after acquiring an additional 2,106 shares in the last quarter. 76.86% of the stock is owned by institutional investors and hedge funds.
Mylan (NASDAQ:MYL) opened at $41.28 on Friday. Mylan has a 52 week low of $29.39 and a 52 week high of $47.82. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $22,106.54, a P/E ratio of 8.77, a price-to-earnings-growth ratio of 1.11 and a beta of 1.35.
Several equities research analysts recently issued reports on MYL shares. Zacks Investment Research lowered shares of Mylan from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. BidaskClub raised shares of Mylan from a “hold” rating to a “buy” rating in a report on Friday, October 27th. Leerink Swann started coverage on shares of Mylan in a report on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 target price for the company. Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the stock a “hold” rating in a report on Tuesday, October 31st. Finally, TheStreet raised shares of Mylan from a “c” rating to a “b-” rating in a report on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. Mylan currently has an average rating of “Buy” and an average price target of $44.89.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.69% of the company’s stock.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.